News | Heart Valve Technology | May 03, 2017

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

Team is first in United States for specific valve-in-valve case

Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve

May 3, 2017 — The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team recently placed the first commercially approved CoreValve Evolut Pro system in Texas. This is also the first Evolut Pro valve placed in a failed bioprosthetic (tissue) aortic valve in the United States.

“The Evolut PRO has a unique ‘skirt’ around the valve that helps minimize leakage; one of the greatest potential risks for TAVR patient outcomes,” said Robert Stoler, M.D., co-medical director of cardiology and medical director, Baylor Heart and Vascular Hospital catheterization lab. “In this procedure, we replaced an old, surgically implanted bioprosthetic aortic valve using a minimally invasive approach, without open-heart surgery.”

During a catheter-based TAVR procedure, an interventional cardiologist or cardiothoracic surgeon makes a small incision in the leg (transfemoral approach), upper chest (direct aortic approach) or shoulder (subclavian approach) to access the vasculature, and then guides the new valve into position to replace the failing aortic valve. Once in place, the device expands and takes over the original valves function to enable blood to flow efficiently out of the heart.

“The addition of the Evolut PRO valve to the program at BHVH continues to bring an advanced generation of research and commercially available valves to aortic stenosis patients in the North Texas region,” Stoler added. “We are pleased to be the first in Texas and one of the first in the U.S. to use this new technology.”

Aortic stenosis is a common problem caused by a narrowing of the heart’s aortic valve due to excessive calcium deposits on the valve leaflets. When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this may cause the heart to weaken, potentially leading to heart failure and increased risk for sudden cardiac death.

Interventional cardiologists and cardiothoracic surgeons on the BHVH medical staff have performed TAVR procedures in patients with aortic stenosis for more than five years and recently reached their 500th TAVR.

For more information: www.medtronic.com

Related Content

Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Overlay Init